Display options
Cite
Talbot SJ, Blair NF, McGill N, et al. An Influenza Virus M2 Protein Specific Chimeric Antigen Receptor Modulates Influenza A/WSN/33 H1N1 Infection In Vivo. Open Virol J. 2013;7:28-36doi: 10.2174/1874357901307010028.
Talbot, S. J., Blair, N. F., McGill, N., Ligertwood, Y., Dutia, B. M., & Johannessen, I. (2013). An Influenza Virus M2 Protein Specific Chimeric Antigen Receptor Modulates Influenza A/WSN/33 H1N1 Infection In Vivo. The open virology journal, 728-36. https://doi.org/10.2174/1874357901307010028
Talbot, Simon J, et al. "An Influenza Virus M2 Protein Specific Chimeric Antigen Receptor Modulates Influenza A/WSN/33 H1N1 Infection In Vivo." The open virology journal vol. 7 (2013): 28-36. doi: https://doi.org/10.2174/1874357901307010028
Talbot SJ, Blair NF, McGill N, Ligertwood Y, Dutia BM, Johannessen I. An Influenza Virus M2 Protein Specific Chimeric Antigen Receptor Modulates Influenza A/WSN/33 H1N1 Infection In Vivo. Open Virol J. 2013;7:28-36. doi: 10.2174/1874357901307010028. Epub 2013 Feb 25. PMID: 23493233; PMCID: PMC3594705.
Copy Download .nbib Format: NLM
Share it on

Open Virol J. 2013;7:28-36. doi: 10.2174/1874357901307010028. Epub 2013 Feb 25.

An Influenza Virus M2 Protein Specific Chimeric Antigen Receptor Modulates Influenza A/WSN/33 H1N1 Infection In Vivo.

The open virology journal

Simon J Talbot, Natalie F Blair, Niolette McGill, Yvonne Ligertwood, Bernadette M Dutia, Ingo Johannessen

Affiliations

  1. University of Edinburgh, Division of Pathway Medicine, Chancellors building, Little France, Edinburgh EH16 4SB, UK.

PMID: 23493233 PMCID: PMC3594705 DOI: 10.2174/1874357901307010028

Abstract

A potential target for the development of universal vaccine strategies against Influenza A is the M2 protein - a membrane protein with a highly conserved extracellular domain. In this study we developed engineered T-cell receptors, by fusing M2-specific antibody sequences with T-cell receptor transmembrane and signaling domains to target influenza infected cells. When expressed on T-cells, these novel T-cell receptors (chimeric antigen receptors - CARs) are able to recognize specific antigens on the surface of target cells via an MHC-independent mechanism. Using an existing monoclonal antibody (14C2) specific for the M2 ectodomain (M2e), we generated an M2-specific CAR. We tested the specificity of this M2 CAR in vitro by measuring the activation of T-cells in response to M2-specific peptides or M2-expressing cell lines. Both Jurkat T-cells and peripheral blood mononuclear cells expressing the M2-specific CAR responded to specific antigen stimulation by upregulating NFAT and producing γ-interferon. To test whether the M2-specific CAR are effective at recognizing influenza infected cells in vivo we used an established BALB/c murine infection model. At day 4 post-infection, when M2 CAR expressing splenocytes could be detected in the lung, the Influenza A/WSN/33 virus titre was around 50% of that in control mice. Although the lung virus titre later increased in the treated group, virus was cleared in both groups of mice by day 8. The results provide support for the development of M2e as a target for cell mediated immunotherapy.

Keywords: Antibody; M2; T-cell; chimeric antigen receptor; influenza A; therapy; virus.

References

  1. Emerg Infect Dis. 2006 Apr;12(4):569-74 - PubMed
  2. Annu Rev Med. 2006;57:139-54 - PubMed
  3. Emerg Infect Dis. 2006 Jan;12(1):48-54 - PubMed
  4. PLoS One. 2010 Dec 28;5(12):e14442 - PubMed
  5. N Engl J Med. 2005 Sep 29;353(13):1363-73 - PubMed
  6. J Biol Chem. 2006 Apr 7;281(14):8997-9000 - PubMed
  7. N Engl J Med. 2005 Dec 22;353(25):2667-72 - PubMed
  8. Nature. 1993 Jun 3;363(6428):418-23 - PubMed
  9. Hum Mol Genet. 2011 Apr 15;20(R1):R93-9 - PubMed
  10. Vaccine. 2009 Oct 23;27(45):6280-3 - PubMed
  11. Vaccine. 2011 Jul 18;29(32):5145-52 - PubMed
  12. Chest. 2006 Jan;129(1):156-68 - PubMed
  13. Nat Immunol. 2006 May;7(5):449-55 - PubMed
  14. N Engl J Med. 2005 Sep 29;353(13):1374-85 - PubMed
  15. PLoS Pathog. 2012;8(11):e1002998 - PubMed
  16. J Virol. 1995 Apr;69(4):2075-81 - PubMed
  17. J Virol. 1988 Aug;62(8):2762-72 - PubMed
  18. Clin Immunol. 2001 Feb;98(2):220-8 - PubMed
  19. Antiviral Res. 2011 Sep;91(3):283-7 - PubMed
  20. Curr Opin Mol Ther. 2010 Feb;12(1):55-63 - PubMed
  21. J Infect Dis. 2006 Mar 15;193(6):751-3 - PubMed
  22. Nature. 2005 Oct 20;437(7062):1108 - PubMed
  23. J Immunol. 2010 Feb 15;184(4):1885-96 - PubMed
  24. Blood. 2002 Nov 1;100(9):3155-63 - PubMed
  25. Antiviral Res. 2000 Oct;48(1):1-16 - PubMed
  26. Nat Rev Immunol. 2002 Jul;2(7):512-9 - PubMed
  27. PLoS One. 2011;6(12):e28445 - PubMed
  28. Expert Rev Vaccines. 2009 Apr;8(4):499-508 - PubMed

Publication Types